Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(4), P. 501 - 501
Published: March 30, 2025
Background/Objectives:
Worldwide,
colon
cancer
is
a
major
cause
of
cancer-related
mortality,
with
an
increasing
incidence
influenced
by
genetic,
environmental,
and
lifestyle
factors.
Despite
advances
in
diagnosis
personalized
treatments,
challenges
remain
improving
patient
prognosis,
particularly
metastatic
colorectal
(mCRC).
Bevacizumab
(BEV),
monoclonal
antibody,
widely
used
treatment.
This
study
aimed
to
analyze
adverse
events
associated
BEV
compared
other
therapies
based
on
data
from
the
EudraVigilance
(EV)
database.
Methods:
A
descriptive
disproportionality
analysis
was
conducted
signals
reported
EV
database
related
BEV.
The
included
comparisons
antineoplastic
such
as
chemotherapy,
targeted
therapy,
immunotherapy.
Patient
demographics,
severity
drug
reactions
(ADRs),
distribution
patterns
were
analyzed
assess
safety
profile
Results:
majority
for
patients
aged
18–64
years
(39.42%)
65–85
(34.08%).
Hypertension,
thromboembolism,
proteinuria,
gastrointestinal
disorders
have
been
most
frequently
reported.
Serious
ADRs,
including
perforations,
hemorrhage,
arterial
observed
93.74%
Individual
Case
Safety
Reports.
higher
likelihood
vascular
endocrine
chemotherapy
therapies.
Immunotherapy
linked
increased
immunological
while
demonstrated
fewer
immune-related
toxicities.
Conclusions:
Continuous
monitoring
necessary
optimize
management,
elderly
or
those
cardiovascular
comorbidities.
Understanding
BEV’s
allows
better
personalization
treatment
strategies,
minimizing
risks
enhancing
therapeutic
outcomes.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(6), P. 2453 - 2453
Published: March 10, 2025
Immunotherapy
is
becoming
a
promising
strategy
for
treating
diverse
cancers.
However,
it
benefits
only
selected
group
of
gastric
cancer
(GC)
patients
since
they
have
highly
heterogeneous
immunosuppressive
microenvironments.
Thus,
more
sophisticated
immunological
subclassification
and
characterization
GC
great
practical
significance
mRNA
vaccine
therapy.
This
study
aimed
to
find
new
further
identify
specific
tumor
antigens
development.
First,
deep
autoencoder
(AE)-based
clustering
was
utilized
construct
the
profile
uncover
four
distinct
immune
subtypes
GC,
labeled
as
Subtypes
1,
2,
3,
4.
Then,
in
silico
prediction
using
machine
learning
methods
performed
accurate
discrimination
classifications
with
an
average
accuracy
97.6%.
Our
results
suggested
significant
clinicopathology,
molecular,
differences
across
subtypes.
Notably,
Subtype
4
characterized
by
poor
prognosis,
reduced
purity,
enhanced
cell
infiltration
activity;
thus,
tumor-specific
associated
were
identified,
customized
developed
immunoinformatic
tools.
Finally,
influence
microenvironment
(TME)
on
treatment
efficacy
assessed,
emphasizing
that
may
benefit
from
this
therapeutic
approach.
Overall,
our
findings
could
help
provide
insights
into
improving
prognosis
immunotherapy
patients.
Molecular Biomedicine,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: March 20, 2025
Abstract
Cancer
ranks
among
the
most
lethal
diseases
worldwide.
Tissue
biopsy
is
currently
primary
method
for
diagnosis
and
biological
analysis
of
various
solid
tumors.
However,
this
has
some
disadvantages
related
to
insufficient
tissue
specimen
collection
intratumoral
heterogeneity.
Liquid
a
noninvasive
approach
identifying
cancer-related
biomarkers
in
peripheral
blood,
which
allows
repetitive
sampling
across
multiple
time
points.
In
field
liquid
biopsy,
representative
include
circulating
tumor
cells
(CTCs),
DNA
(ctDNA),
exosomes.
Many
studies
have
evaluated
prognostic
predictive
roles
CTCs
ctDNA
Although
these
limitations,
results
appear
consistently
demonstrate
correlations
high
CTC
counts
mutations
with
lower
survival
rates
cancer
patients.
Similarly,
reduction
throughout
therapy
may
be
potential
indicator
treatment
response
advanced
Moreover,
biochemical
characteristics
can
provide
information
about
biology
as
well
resistance
mechanisms
against
targeted
therapy.
This
review
discusses
current
clinical
applications
patients,
emphasizing
its
possible
utility
outcome
prediction
decision-making.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(4), P. 501 - 501
Published: March 30, 2025
Background/Objectives:
Worldwide,
colon
cancer
is
a
major
cause
of
cancer-related
mortality,
with
an
increasing
incidence
influenced
by
genetic,
environmental,
and
lifestyle
factors.
Despite
advances
in
diagnosis
personalized
treatments,
challenges
remain
improving
patient
prognosis,
particularly
metastatic
colorectal
(mCRC).
Bevacizumab
(BEV),
monoclonal
antibody,
widely
used
treatment.
This
study
aimed
to
analyze
adverse
events
associated
BEV
compared
other
therapies
based
on
data
from
the
EudraVigilance
(EV)
database.
Methods:
A
descriptive
disproportionality
analysis
was
conducted
signals
reported
EV
database
related
BEV.
The
included
comparisons
antineoplastic
such
as
chemotherapy,
targeted
therapy,
immunotherapy.
Patient
demographics,
severity
drug
reactions
(ADRs),
distribution
patterns
were
analyzed
assess
safety
profile
Results:
majority
for
patients
aged
18–64
years
(39.42%)
65–85
(34.08%).
Hypertension,
thromboembolism,
proteinuria,
gastrointestinal
disorders
have
been
most
frequently
reported.
Serious
ADRs,
including
perforations,
hemorrhage,
arterial
observed
93.74%
Individual
Case
Safety
Reports.
higher
likelihood
vascular
endocrine
chemotherapy
therapies.
Immunotherapy
linked
increased
immunological
while
demonstrated
fewer
immune-related
toxicities.
Conclusions:
Continuous
monitoring
necessary
optimize
management,
elderly
or
those
cardiovascular
comorbidities.
Understanding
BEV’s
allows
better
personalization
treatment
strategies,
minimizing
risks
enhancing
therapeutic
outcomes.
